Arbutus Biopharma Stock Quote ABUS - Stock Price, News, Charts, Message Board, Trades

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Arbutus Biopharma Corporation (ABUS) Quote

Arbutus Biopharma Corporation (ABUS)

2.72

-0.02

(-0.73%)

At close: April 25 4:00PM

Delayed by 15 minutes

2.72

-0.02

( -0.73% )

After Hours: 5:29PM

Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Current Price

2.72

Bid

2.71

Ask

2.84

Volume

323,341

2.68 Day's Range 2.75

1.69 52 Week Range 3.29

Market Cap

Previous Close

2.74

Open

2.74

Last Trade

Last Trade Time

16:39:41

Financial Volume

$ 878,201

VWAP

2.716

Average Volume (3m)

1,446,339

Shares Outstanding

179,492,199

Dividend Yield

-

PE Ratio

-6.70

Earnings Per Share (EPS)

-0.41

Revenue

18.14M

Net Profit

-72.85M

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.tekmirapharm.com

Headquarters

Burnaby, British Columbia, Can

Founded

1970

Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABUS. The last closing price for Arbutus Biopharma was $2.74. Over the last year, Arbutus Biopharma shares have traded in a share price range of $ 1.69 to $ 3.29.

Arbutus Biopharma currently has 179,492,199 shares outstanding. The market capitalization of Arbutus Biopharma is $488.22 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -6.70.

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to...

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to...

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.06	-2.15827338129	2.78	2.81	2.635	824256	2.71771105	CS
4	0.13	5.01930501931	2.59	3.29	2.3	2193323	2.94398482	CS
12	0.32	13.3333333333	2.4	3.29	2.265	1446339	2.82673099	CS
26	0.9	49.4505494505	1.82	3.29	1.7	1057516	2.57893628	CS
52	0.1	3.81679389313	2.62	3.29	1.69	841612	2.4449313	CS
156	-0.51	-15.7894736842	3.23	6.5	1.69	1938247	3.49645599	CS
260	-0.03	-1.09090909091	2.75	9	0.81	2062469	3.66492074	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TVGNTevogen Bio Holdings Inc	$ 1.33 (56.47%)	219.96k
PEGYPineapple Energy Inc	$ 0.0729 (40.46%)	37.55M
GGLLDirexion Daily GOOGL Bull 2X ETF	$ 45.30 (25.76%)	179.37k
NUZENuZee Inc	$ 1.45 (18.85%)	11.12k
ELWSEarlyworks Co Ltd	$ 0.873 (18.72%)	1.92M
VINCVincerx Inc	$ 0.736 (-17.92%)	331.78k
ACONAclarion Inc	$ 0.325 (-17.24%)	1.28M
ATXIAvenue Therapeutics Inc	$ 0.0992 (-15.21%)	454.59k
WORXSCWorx Corporation	$ 2.36 (-14.49%)	345.48k
GGLSDirexion Daily GOOGL	$ 13.3801 (-13.00%)	189.64k
PEGYPineapple Energy Inc	$ 0.0729 (40.46%)	37.55M
GOOGLAlphabet Inc	$ 176.39 (13.07%)	10.46M
SQQQProShares UltraPro Short QQQ	$ 11.56 (-3.67%)	8.17M
INTCIntel Corporation	$ 32.20 (-8.29%)	7.07M
GOOGAlphabet Inc	$ 178.261 (12.86%)	5.4M

mick

mick 5 days ago

TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:

Monksdream

Monksdream 3 weeks ago

db7

db7 3 weeks ago

looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june

mick

mick 3 weeks ago

ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890

mick

mick 3 weeks ago

ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890

mick

mick 3 weeks ago

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

mick

mick 3 weeks ago

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

mick

mick 3 weeks ago

Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

mick

mick 3 weeks ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

Paullee

Paullee 3 weeks ago

07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.

MWM

MWM 3 weeks ago

Watching all 3 stocks. $ABUS is kind of moving...

db7

db7 3 weeks ago

was going to take all '3' to explode imo..

MWM

MWM 3 weeks ago

Yes, I'm trying to read it myself

db7

db7 3 weeks ago

decision is out; looks like arbutus won '2' and moderna '1' .. please confirm

db7

db7 1 month ago

https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/

Desert dweller

Desert dweller 2 months ago

My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.

Desert dweller

Desert dweller 2 months ago

Handle on twitter is @DesertDweller93

MWM

MWM 2 months ago

Great post!

What’s your handle on Twitter?

Desert dweller

Desert dweller 2 months ago

I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.

MWM

MWM 2 months ago

A couple bad headlines for MRNA of late. Here is one of todays...

Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s

db7

db7 2 months ago

yes, quite the drop yesterday and today on mrna... g/l!

MWM

MWM 2 months ago

Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...

db7

db7 3 months ago

https://twitter.com/themightyforego/status/1755757415750865356?s=46

MWM

MWM 3 months ago

And also

Get on Twitter Damn it lol!

db7

db7 3 months ago

wasn't.. will check it out... thanks!!

MWM

MWM 3 months ago

Also

Are you watching VKTX?

MWM

MWM 3 months ago

Thanks for pointing this out

db7

db7 3 months ago

interesting (although stock isn't reacting): "Watching Arbutus Biopharma; Hearing Jefferies Issues Note On Arbutus Biopharma On LNP Markman Hearing Saying Judge Favors Company Over Moderna. -BENZINGA"

db7

db7 3 months ago

"Markman Hearing set for February 8, 2024 – court will hear arguments on claim construction and expected to issue its order within 60 days of conclusion of the hearing"

from 1/8/2024 Arbutus presentation...

db7

db7 3 months ago

2,000,000 share block trade woke some people up ...........

db7

db7 3 months ago

"With respect to the Moderna lawsuit, fact discovery is currently on-going with the claim construction hearing scheduled for February 8, 2024. According to the Court Scheduling Order, which was issued on March 21, 2023, the court is expected to issue its claim construction order within 60 days of conclusion of the claim construction hearing."

https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-2024-corporate-objectives-and-provides

db7

db7 4 months ago

from what i'm reading, apparently people are not in love with today's update... 1) moderna trial in 2025 when i think it was expected this year and 2) using 'durvalumab' in a trial instead of their own '101' which some say may mean safety signal seen in '101'(?)

all noise to me; markman is why i came here in the first place......

g/l!

db7

db7 4 months ago

with there being several catalysts, it 'possibly' sets up some safety if only 1 goes bad(?)

MWM

MWM 4 months ago

I’ll start watching for any unusual options heading into February

db7

db7 4 months ago

ABUS gets 20% of win and then also owns 12%(?) of Genevant as well...

db7

db7 4 months ago

ROIV safer for sure but %-wise ABUS would benefit more......

MWM

MWM 4 months ago

$ROIV might be the better play however. Will have to look it up again but I think ROIV would receive the majority of any verdict?

MWM

MWM 4 months ago

No, I myself didn’t realize it. Front screen now, thanks db!

When are you going to set up an account on Twitter!!!

db7

db7 4 months ago

db7

db7 4 months ago

correct; pfizer date not yet set 'but' Moderna has... sorry, if I misinterpreted your post...

MWM

MWM 4 months ago

I read this wrong. So there are two trails? One against PFE/BNTX and one against MRNA.
Hmmm

MWM

MWM 4 months ago

A trial date has not been set, but the trial is expected to commence in the first half of 2025. The lawsuit against Pfizer/BioNTech is ongoing and a date for a claim construction hearing has not been set.

db7

db7 4 months ago

Moderna Claims Construction (ie: Markman hearing) 2/8/2024 with decision expected within 60 days; 'this' should be an event for sure.... positive or negative, we'll have to wait and see- g/l!

MWM

MWM 4 months ago

For now, almost all small biotechs have participated in the melt up to close 2023. We will have to see where 2024 takes us. Their biggest catalyst, the lawsuit with MRNA and BNTX is still a ways away.
But it’s one that is always on my radar.

db7

db7 4 months ago

going to be a busy 1st half of the year here...

db7

db7 4 months ago

https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-2024-corporate-objectives-and-provides

mick

mick 4 months ago

https://www.otcmarkets.com/stock/ABUS

MWM

MWM 5 months ago

I’ll be watching thanks

db7

db7 5 months ago

ABUS ($1.90) 'might' be time to put this one back on radar? https://stocktwits.com/bs010101/message/552178969

db7

db7 5 months ago

Arbutus Biopharma

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions